Bank of Montreal
PBYI icon

Bank of Montreal’s Puma Biotechnology PBYI Stock Holding History

Bank of Montreal’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-4,000
Closed -$467K – 4110
2015
Q2 		$467K Buy
+4,000
New +$724K ﹤0.01% 2004

Other funds holding PBYI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Bank of Montreal's PBYI Position: Q3 2024 in Review

Bank of Montreal sold out of Puma Biotechnology (PBYI) in Q3 2024, closing a stake of 70,352 shares — an estimated $232K sold.

Bank of Montreal first reported a position in PBYI in Q2 2014 and held it in 31 quarters. The position peaked at $11.3M in Q3 2017. 100 funds tracked by Wall St. Rank hold PBYI as of Q3 2024.

  • Bank of Montreal reported no remaining Puma Biotechnology position as of Q3 2024 after selling out during the quarter.
  • Bank of Montreal sold 70,352 Puma Biotechnology shares in Q3 2024, an estimated $232K.
  • Bank of Montreal first reported a position in Puma Biotechnology in Q2 2014 and held it in 31 quarters.
  • Bank of Montreal's Puma Biotechnology position peaked at $11.3M in Q3 2017.
  • 100 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2024.

Based on Bank of Montreal's 13F filing for Q3 2024, filed 13 Nov 2024.